ライフサイエンスコーパス: aAPC

1 aAPC are based on artificial membrane bilayers containin

2 aAPC-generated cells also produced more of each cytokine

3 aAPC-induced cultures showed robust antigen-specific CTL

4 aAPCs modified to coexpress OX40L or 4-1BBL expanded UCB

5 s mostly expand naive cells, anti-CD3/4-1BBL aAPCs preferentially expand memory cells, resulting in s

6 g HLA-A2-Fc fusion proteins linked to 4-1BBL aAPCs, 3-log expansion of Ag-specific CD8+ CTL was induc

7 The allogeneic aAPC, RTX-321, comprised of human leukocyte antigen-A*02

8 ass I/II and CD1 expression, we generated an aAPC expressing CD1c as the sole Ag-presenting molecule.

9 scribes the translation of the SB system and aAPC for use in clinical trials and highlights how a nim

10 by stimulation with peptide-loaded moDCs and aAPCs, T cell function, assessed by expression of IL-2,

11 of human polyclonal T cells (artificial APC (aAPC)).

12 study, using a novel CD1c(+) artificial APC (aAPC)-based system, we isolated human CD1c-restricted au

13 the presence of K562-derived artificial APC (aAPCs) and cytokines.

14 Artificial APCs (aAPCs) consisting of magnetic beads coated with Abs to H

15 stimulation signals, MHC II artificial APCs (aAPCs) expand cognate murine CD4(+) T cells, including r

16 Artificial APCs (aAPCs) genetically modified to express selective costimu

17 (moDCs) or HLA-A2-Ig-based artificial APCs (aAPCs).

18 Cell-based aAPCs can effectively expand cytolytic CD8+ cells, but o

19 uman cytolytic CD8+ T cells using cell-based aAPCs providing costimulation via 4-1BB vs CD28.

20 These studies show the value of HLA-Ig-based aAPCs for reproducible expansion of disease-specific CTL

21 HLA-Ig-based aAPCs were used to induce and expand CTLs specific for c

22 stly, human leukocyte antigen class II-based aAPCs expand rare subsets of functional, antigen-specifi

23 Compared with beads, aAPCs had similar expansion properties while significant

24 When stimulated with this CD1c(+) aAPC presenting endogenous lipids, a subpopulation of pr

25 Whereas anti-CD3/anti-CD28 aAPCs mostly expand naive cells, anti-CD3/4-1BBL aAPCs p

26 sion did not occur using HLA-A2-Fc/anti-CD28 aAPCs.

27 Using an artificial antigen-presenting cell (aAPC) that can process both the N- and C-termini of endo

28 specific artificial antigen presenting cell (aAPC), coupled with a rapid expansion protocol (REP) as

29 ed with artificial antigen-presenting cells (aAPC) can selectively propagate and thus retrieve CAR(+)

30 NHL on artificial antigen presenting cells (aAPC) in the presence of human interleukin (IL)-2 and IL

31 CD19(+) artificial antigen-presenting cells (aAPC).

32 s using artificial antigen-presenting cells (aAPCs) and reporter T cells.

33 Artificial antigen-presenting cells (aAPCs) are an emerging technology to induce therapeutic

34 veloped artificial antigen-presenting cells (aAPCs) expressing ligands for the T-cell receptor (TCR)

35 use of artificial antigen presenting cells (aAPCs) in the clinic as cancer immunotherapeutics are hi

36 l-based artificial antigen-presenting cells (aAPCs) preloaded with anti-CD3/28 mAbs to achieve higher

37 ls into artificial antigen-presenting cells (aAPCs) presenting a peptide bound to the major histocomp

38 issue, artificial antigen-presenting cells (aAPCs) were made by coupling a soluble human leukocyte a

39 In conclusion, aAPCs expand T(CM) that have extensive replicative capac

40 high expression of CD137L by a K562-derived aAPC cell line could sustain NK cell expansion by 3 x 10

41 ls similar to CD137L-expressing K562-derived aAPCs.

42 Engineered aAPC may have immediate application for basic and clinic

43 UCB Tregs expanded with 4-1BBL expressing aAPCs had decreased levels of proapoptotic bim.

44 culture conditions of expanding T cells from aAPCs to moDCs, and moDCs to aAPCs, reversed the phenoty

45 Overall, MHC II aAPCs provide a promising approach for harnessing target

46 Moreover, MHC II aAPCs provide help signals that enhance antitumor functi

47 Further stimulation with peptide-loaded aAPC increased purity to >99% Ag-specific T cells.

48 Peptide-loaded aAPC were not sufficient to induce resting CD4 T(CM) to

49 Tregs expanded with nonmodified or modified aAPCs versus beads resulted in higher survival associate

50 cle artificial antigen-presenting cell (nano-aAPC) ex vivo expansion approach and an in vivo delivery

51 Our findings suggest that nano-aAPC-induced T(RM)-like cells, coupled with a hydrogel d

52 Using the nano-aAPC platform, we expanded functional antigen-specific m

53 tly greater extent than bead- or nonmodified aAPC cultures, reaching mean expansion levels exceeding

54 p signals that enhance antitumor function of aAPC-activated CD8(+) T cells in a mouse tumor model.

55 mutein of IL-21 bound to the cell surface of aAPC that replaced the need for soluble IL-21.

56 ly upon CD137 engagement and the presence of aAPCs.

57 Among the variety of aAPCs that have been studied, acellular beads expressing

58 To fully replace natural APCs, an optimized aAPC must present antigen (signal 1), provide costimulat

59 ved when we used either soluble tetramers or aAPC in which MHC-peptide complexes were uniformly distr

60 e release of IL-2 from biodegradable polymer aAPCs (now termed paAPCs) can significantly alter the ba

61 novel technique to generate patient-specific aAPCs, that might have the potential to revolutionize th

62 Using T cell receptor (TCR)-specific aAPCs carrying co-stimulatory molecules and major histoc

63 TNF-alpha, MIP1beta, and CD107a, showed that aAPC-generated CD8(+) T cells were multifunctional, wher

64 -down peptide-MHCs from cell lysates and the aAPCs generated using this technique were able to induce

65 These aAPCs reproducibly activate and rapidly expand polyclona

66 These results suggest that this aAPC-based approach enables the biochemical identificati

67 ng T cells from aAPCs to moDCs, and moDCs to aAPCs, reversed the phenotypes.

68 novel approach for UCB Treg expansion using aAPCs, including those coexpressing OX40L or 4-1BBL.